Back to Archived News
Health Enhancement Products, Inc. Announces the Issuance of a US Patent for Its Proprietary ProAlgaZyme Algal Extract and the Treatment of Disease
Thursday, October 14, 2010
Scottsdale, AZ -- Health Enhancement Products, Inc. (OTCBB: HEPI) received notification of patent issuance regarding its proprietary algal extract ProAlgaZyme® (PAZ™). The patent, titled "Composition and Use of Phyto-Percolate for the Treatment of Disease," describes the general makeup of PAZ™ and its unique ability to address a variety of common maladies, among them inflammation, oxidative stress and cholesterol regulation.
"The patent is another step in establishing the credibility of our intellectual property and creating a perimeter around what PAZ is capable of delivering," states John Gorman, HEPI Director. "It's another layer of substantiation and protection for the processes and bioactive compounds that are integral to PAZ and its future derivatives. Earlier this year, we filed two patents for regulation of healthy cholesterol management. We intend to build on that IP portfolio and also expect to be filing additional patents in the very near future."
The patent formally issues October 5th as US Patent No. 7,807,622. A "Continuation" has also been filed which allows us to introduce new information recently developed as the HEPI science team continues its work on bioactive compounds that maintain a healthy cholesterol balance.
About Health Enhancement Products, Inc.
Health Enhancement Products, Inc. (OTCBB: HEPI) is a health & wellness company engaged in the development of a product comprised of pure, all-natural compounds that can be used as a dietary supplement and food additive. The Company's product is ProAlgaZyme® (PAZ™), a liquid product drawn from living algae grown in purified water. The water in which the algae are grown is drawn off, filtered and bottled under the trademark ProAlgaZyme®.
Safe Harbor Statement
Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including the timing of completion of a trial, actual future clinical trial results being different than the results the company has obtained to date, and the company's ability to secure funding. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and those actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.
Back to Archived News